These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 14603339)

  • 1. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
    Mishra S; Zhang B; Groffen J; Heisterkamp N
    Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
    Nakajima A; Tauchi T; Sumi M; Bishop WR; Ohyashiki K
    Mol Cancer Ther; 2003 Mar; 2(3):219-24. PubMed ID: 12657715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
    Reichert A; Heisterkamp N; Daley GQ; Groffen J
    Blood; 2001 Mar; 97(5):1399-403. PubMed ID: 11222386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
    O'Dwyer M
    Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
    Kaur P; Feldhahn N; Zhang B; Trageser D; Müschen M; Pertz V; Groffen J; Heisterkamp N
    Mol Cancer; 2007 Oct; 6():67. PubMed ID: 17958915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Sherr CJ
    Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
    Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
    Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
    Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
    Brain J; Saksena A; Laneuville P
    Leuk Res; 2002 Nov; 26(11):1011-6. PubMed ID: 12363470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
    Ottmann OG; Hoelzer D
    Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a.
    Zhang B; Groffen J; Heisterkamp N
    Blood; 2005 Aug; 106(4):1355-61. PubMed ID: 15860663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
    le Coutre P; Mologni L; Cleris L; Marchesi E; Buchdunger E; Giardini R; Formelli F; Gambacorti-Passerini C
    J Natl Cancer Inst; 1999 Jan; 91(2):163-8. PubMed ID: 9923858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
    Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
    Hoover RR; Mahon FX; Melo JV; Daley GQ
    Blood; 2002 Aug; 100(3):1068-71. PubMed ID: 12130526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
    Thomas X
    Bull Cancer; 2007 Oct; 94(10):871-80. PubMed ID: 17964981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.
    Hallböök H; Barbany G; Aleskog A; Björnberg A; Larsson R; Sundström C; Lindhagen E
    Anticancer Drugs; 2005 Jul; 16(6):631-4. PubMed ID: 15930891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
    von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J
    Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.